User:Mr. Ibrahem/Methylscopolamine

Mr. Ibrahem/Methylscopolamine

Clinical data
Trade names	Pamine, Extendryl, AlleRx, Others
Other names	Methylscopolamine bromide
AHFS/Drugs.com	Monograph
MedlinePlus	a606008
Drug class	Antimuscarinic
Pharmacokinetic data
Elimination half-life	3–4 hrs
Identifiers
IUPAC name (1R,2S,4R,5S,7R)-{[(2R)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane
Chemical and physical data
Formula	C18H24NO4
Molar mass	318.388 g/mol (398.297 g/mol with bromide) g·mol−1
3D model (JSmol)	Interactive image
SMILES OC[C@H](c1ccccc1)C(=O)O[C@H]2C[C@@H]3[N+](C)(C)[C@H](C2)[C@H]4O[C@@H]34
InChI InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12-,13-,14-,15+,16-,17+/m1/s1 Y Key:LZCOQTDXKCNBEE-IKIFYQGPSA-N Y
(verify)

Methylscopolamine, also known as methscopolamine, was a medication used to treat stomach ulcers. Its use has mostly been replaced by proton pump inhibitors and H2 blockers which are more effective. It is taken by mouth.

Common side effects include dry mouth, decreased sweating, blurry vision, and increased intraocular pressure. Other side effects may include allergic reactions, sleepiness, and heat stroke. It is an antimuscarinic which acts by blocking the acetylcholine.

Methylscopolamine was patented in 1902 and approved for medical use in 1947. In the United States 60 tablets of 2.5 mg costs about 32 USD as of 2021.